Omega-3 fatty acids are among the few supplements with randomized evidence for all-cause mortality reduction. Here is what the VITAL trial actually showed, who benefits most, and which products deliver the dose and form the research uses.
Of all the supplements discussed in longevity circles, omega-3 fatty acids have the largest randomized trial base and one of the most surprising research stories of the past decade. After years of conflicting meta-analyses — many of which pooled extremely low-dose trials with therapeutic-dose trials — the 25,871-participant VITAL trial published in the *New England Journal of Medicine* in 2019 provided the clearest signal yet: at 1 g/day of marine omega-3, the study found a 28% reduction in fatal myocardial infarction and statistically significant reductions in total MI, with a particularly strong signal in people who ate little fish at baseline.
This is not a niche finding. Cardiovascular disease remains the leading cause of death, and a 28% reduction in fatal MI from a supplement with an excellent safety profile and a cost of under $0.50/day represents one of the best risk-adjusted longevity investments available without a prescription.
The mechanism extends beyond the heart. EPA and DHA are the primary substrates for specialized pro-resolving mediators — resolvins, protectins, and maresins — which actively terminate inflammation. They are also essential for brain membrane structure, BDNF production, and synaptic plasticity. The omega-3 story is not just cardiovascular: it is a story about maintaining the anti-inflammatory and neuroprotective infrastructure that underpins healthspan.
Long-chain omega-3 fatty acids — eicosapentaenoic acid (EPA, 20:5n-3) and docosahexaenoic acid (DHA, 22:6n-3) — are structurally and functionally distinct from alpha-linolenic acid (ALA), the short-chain omega-3 found in flaxseed, walnuts, and chia. The body converts ALA to EPA and DHA inefficiently (roughly 5–10% for EPA, less than 1% for DHA). Dietary or supplemental EPA and DHA are not interchangeable with ALA — they are the biologically active forms.
EPA's primary roles:
DHA's primary roles:
The practical implication: EPA and DHA have overlapping but distinct effects. Cardiovascular and inflammatory applications favor EPA; neurological and DHA-specific membrane maintenance favors DHA. Most longevity protocols benefit from both, making a balanced EPA+DHA supplement the default — with EPA-dominant products reserved for those with primarily cardiovascular or inflammatory goals.
The VITAL trial randomized 25,871 US adults (no prior CVD or cancer) to omega-3 fatty acids (1 g/day as Omacor, providing 840 mg EPA+DHA) or placebo, with a median follow-up of 5.3 years. The pre-specified primary cardiovascular endpoint did not reach significance overall — but the subgroup analyses revealed the most important finding: in participants who consumed less than 1.5 servings of fish per week (the majority of the US population), the reduction in major adverse cardiovascular events was 19%, and the reduction in MI specifically was 28%.
This pattern is consistent with a ceiling effect — people already eating adequate fatty fish have near-optimal EPA and DHA tissue levels, leaving less room for supplementation to produce measurable benefit. The finding reframes how to interpret the omega-3 literature: if you eat fatty fish 2+ times per week, supplementation may produce modest additional benefit; if you eat little fish, the benefit is substantial.
A 2021 meta-analysis in *Mayo Clinic Proceedings* pooling 40 randomized trials (135,267 participants) found omega-3 supplementation significantly reduced: total MI (−13%), fatal MI (−35%), CHD death (−9%), and total CVD events (−8%). The dose-response was clear — higher doses produced larger effect sizes.
The REDUCE-IT trial (2018) randomized 8,179 high-cardiovascular-risk patients on statins to icosapentaenoic acid (EPA only, 4 g/day as Vascepa) or mineral oil placebo. The result: 25% relative risk reduction in major cardiovascular events. This trial demonstrated that very high-dose purified EPA — far above standard supplement doses — has a pharmacological cardiovascular effect beyond what diet could provide. REDUCE-IT is relevant to longevity medicine for the subset of patients with hypertriglyceridemia or established cardiovascular risk.
The relationship between DHA and cognitive aging is epidemiologically robust but trial results are mixed — largely because most dementia prevention trials enrolled participants who already showed cognitive decline, making supplementation a late intervention. The more consistent finding is in healthy aging adults: a 2022 Cochrane review found that omega-3 supplementation produced statistically significant improvement in cognitive composite scores in adults without dementia across 14 trials.
Plasma DHA levels correlate with brain DHA content and gray matter volume in imaging studies. Individuals with plasma DHA in the lowest quartile have approximately 47% greater risk of dementia over 9 years of follow-up (Framingham Heart Study). This is not evidence that supplementation prevents dementia, but it strongly suggests that DHA adequacy is part of the brain maintenance picture.
A 2021 meta-analysis in *BMJ* pooling 17 randomized trials found marine omega-3 supplementation reduced all-cause mortality by 7% (RR 0.93, 95% CI 0.88–0.98). The signal is modest but statistically robust across independent datasets and consistent with the cardiovascular mortality reductions driving it.
General longevity/cardiovascular prevention (no established CVD): 1–2 g combined EPA+DHA per day. This covers the VITAL trial dose and is the minimum effective range.
Active cardiovascular risk reduction or elevated triglycerides: 2–4 g combined EPA+DHA per day. This range is where pharmacological triglyceride-lowering effects emerge (–20–30% reduction). The upper end approaches REDUCE-IT territory.
Cognitive/DHA-priority goal: ensure at least 500–1,000 mg DHA per day. This is within the 1–2 g combined EPA+DHA range if the product has a roughly balanced ratio.
Practical note: omega-3 absorption is dramatically improved with a fat-containing meal — bioavailability increases by 50–200% compared to fasting. Always take omega-3 with food. Capsules taken with dinner are the most reliable protocol.
The VITAL trial used 1 g/day. For people eating little fish, this produced a 28% reduction in fatal MI. Whether 2 g/day would have produced a 50% reduction is not known — but the dose-response meta-analyses suggest that higher doses increase the effect.
After the evidence section, the practical question is which product delivers the right dose in a form the body can actually absorb.
This is the most important quality variable in fish oil and the one most consumers overlook.
Ethyl ester (EE) form is the most common form sold in the US supplement market and in many pharmaceutical omega-3 products (including the original Lovaza). EE is a semi-synthetic form created during the concentration process — the fatty acids are stripped from their glycerol backbone and esterified to ethanol. The result is a concentrated omega-3 product that is less expensive to manufacture but significantly less bioavailable.
Triglyceride (TG) form is the natural molecular format in which omega-3s exist in fish tissue. TG-form omega-3 is absorbed approximately 70% better than EE form in controlled bioequivalence studies (Dyerberg et al., *Prostaglandins Leukot Essent Fatty Acids*, 2010).
Re-esterified triglyceride (rTG) form takes concentrated EE omega-3 and re-attaches it to a glycerol backbone, producing a triglyceride form from a concentrated product. This is the best of both worlds: high EPA+DHA concentration per capsule with TG-form absorption. Nordic Naturals Ultimate Omega uses rTG form.
Phospholipid omega-3 (from krill oil) has comparable or slightly better absorption to TG form but provides substantially less EPA+DHA per dollar. At equivalent doses, krill oil costs 3–5× more than quality fish oil. Unless there is a specific reason to prefer krill (some people prefer smaller capsules or the choline co-factor), fish oil TG form is more cost-effective.
Practical test for rancidity: omega-3 fatty acids are highly susceptible to oxidation. Rancid fish oil generates lipid peroxides that may be harmful rather than beneficial. Crack open a capsule — fresh TG-form fish oil should smell faintly of lemon or be nearly odorless. Strong, offensive fish smell indicates oxidation. Buy from brands that publish Certificate of Analysis documents or TOTOX (total oxidation) values.
Thorne's Super EPA provides 425 mg EPA and 100 mg DHA per soft gel — intentionally EPA-dominant for people targeting triglyceride reduction, inflammatory conditions, or cardiovascular risk specifically. NSF certified. Molecular distillation purified. Suitable for those who prefer separate DHA supplementation or whose physician has recommended high-EPA protocols.
Carlson Labs uses wild-caught Alaskan pollock and publishes third-party TOTOX oxidation values — one of the few mass-market brands that is genuinely transparent about freshness. TG form. 1,600 mg EPA+DHA per 2-teaspoon liquid dose (or equivalent softgels). The liquid form provides the highest dose per dollar and is well-tolerated by most people when added to food.
A 2015 Consumer Lab analysis tested 32 fish oil products sold in the US and found that 10 of them had oxidation levels exceeding the international voluntary standard (TOTOX > 26 meq/kg), and none disclosed this information on their labels. A 2021 analysis of New Zealand supplements found similar rates of oxidation.
Oxidized omega-3 products produce malondialdehyde and 4-hydroxynonenal — reactive aldehydes that, paradoxically, may increase cardiovascular inflammation rather than reduce it. This is the primary concern with cheap fish oil that has sat in a warehouse for months.
Signs of a trustworthy omega-3 product:
With a CGM: omega-3 supplementation modestly improves insulin sensitivity and significantly reduces postprandial triglyceride spikes. Users wearing CGMs often notice reduced glucose volatility after meals when consistently supplementing omega-3. See our continuous glucose monitor guide.
With berberine or metformin: omega-3 and AMPK activators work on complementary metabolic pathways. Omega-3 reduces hepatic VLDL secretion and improves lipid profile; berberine reduces fasting glucose. No adverse interaction; the combination is used clinically.
What most multivitamins miss: fish oil is almost never included in a multivitamin at effective doses, which is the single biggest nutritional gap most people have after choosing a quality multivitamin. See our men's multivitamin guide and women's guide.
With red light therapy: EPA and DHA are primary substrates for resolvin and protectin synthesis, the same pro-resolution pathways that near-infrared light activates via cytochrome c oxidase. The mechanistic overlap suggests potential synergy in reducing baseline systemic inflammation.
Does omega-3 thin the blood dangerously?
At standard supplement doses (1–4 g/day), the antiplatelet effect of omega-3 is modest and clinically insignificant in healthy individuals. The concern about surgical bleeding is largely theoretical at supplement doses — clinical guidelines do not require stopping omega-3 before elective surgery below 3 g/day. At very high doses (above 4 g/day), discuss with a physician if you are on anticoagulants.
Is plant-based (algal) omega-3 as effective as fish oil?
Algal oil is the direct source of DHA that fish accumulate from eating algae. It is an excellent option for vegetarians and vegans and provides equivalent DHA at matched doses. Most algal products are DHA-dominant with less EPA, so check the label. Sustainability argument: algal DHA avoids the fish catch chain entirely.
How long before I see effects on lipids?
Triglyceride reduction is typically measurable at 8 weeks with consistent dosing at 2–4 g EPA+DHA/day. LDL effects vary by individual and product — TG-form omega-3 generally produces smaller LDL increases than ethyl ester form. Get a fasting lipid panel at baseline and at 12 weeks.
Can I get enough from diet alone?
Two servings per week of fatty fish (salmon, mackerel, sardines, herring) provides approximately 500–800 mg EPA+DHA per day — below the 1–2 g/day associated with cardiovascular benefit in trials. Most people eating Western diets consume fewer than 100 mg/day of EPA+DHA. Supplementation is not a luxury for this population — it is a correction of a meaningful deficiency.
Why don't my joint supplements count?
Most glucosamine/chondroitin or joint support products that list fish oil contain 300 mg or less — well below the 1 g/day threshold. They do not substitute for a standalone omega-3 product.